Pharmaceutical applications of cyclodextrins: Basic science and product development

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 11, 2010, Pages 1607-1621

  Loftsson, Thorsteinn ^a   Brewster, Marcus E ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

biopharmaceutical characteristics; cyclodextrin containing formulations; cyclodextrins; pharmaceutical applications; solubilization

Indexed keywords

8 CHLOROTHEOPHYLLINE; ARIPIPRAZOLE; BENEXATE; CAVERJECT DUAL; CEFDITOREN PIVOXIL; CEFOTIAM; CEFOTIAM HEXETIL; CEPHALOSPORIN; CERENIA; CETIRIZINE; CETRIZIN; CHLORDIAZEPOXIDE; CISAPRIDE; CLOROCIL; CYCLODEXTRIN DERIVATIVE; DEXAMETHASONE; DEXTROMETHORPHAN; DIPHENHYDRAMINE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL; GLYCERYL TRINITRATE; GLYMESASON; INDOMETACIN; IODINE; ITRACONAZOLE; LIMAPROST; MELOXICAM; MENA GARGLE; MITOEXTRA; MITOMYCIN; MOBITIL; NICOTINE; NICOTINE GUM; NIMEDEX; NIMESULIDE; NITROPEN; OMEBETA; OMEPRAZOLE; OPALMON; PIROXICAM; PIROXICAM BETA CYCLODEXTRIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAVASTIN; RYNATHISOL; STADA; TEBOROXIME TC 99M; TIAPROFENIC ACID; TRANSILLIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAREN OPHTHA; VORICONAZOLE; ZIPRASIDONE;

DRUG ABSORPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; REVIEW; SUPPOSITORY; TABLET; UPPER GASTROINTESTINAL BLEEDING;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 78649654159     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01030.x     Document Type: Review

References (124)

1. Villiers A,. Sur la fermentation de la fécule par l'action du ferment butyrique. Compt Rend Acad Sci 1891; 112: 536-538.
2. Schardinger F,. Über Thermophile Bakterien aus verschiedenen Speisen und Milch, sowie über einige Umsetzungsprodukte derselben in kohlenhydrathaltigen Nährlösungen, darunter krystallisierte Polysaccharide (Dextrine) aus Stärke. Z Untersuch Nahr Genussm 1903; 6: 865-880.
3. Cramer F,. Einschlussverbindungen. Berlin: Springer-Verlag, 1954.
4. Loftsson T, Duchêne D,. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007; 329: 1-11.
5. Freudenberg K, et al. Verfahren zur Herstellung von Einschlusverbindungen physiologisch wirksamer organischer Verbindungen. Germany Patent No. 895 769, 1953.
6. Loftsson T, Brewster ME,. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996; 85: 1017-1025.
7. Rajewski RA, Stella VJ,. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996; 85: 1142-1168.
8. Irie T, Uekama K,. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86: 147-162.
9. Thompson DO,. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 1997; 14: 1-104.
10. D'Souza VT, Lipkowitz KB,. Cyclodextrins. Chem Rev 1998; 985: 1741-1742.
11. Uekama K,. Cyclodextrins in drug delivery. Adv Drug Deliv Rev 1999; 36: 1-141.
12. Loftsson T, Masson M,. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001; 225: 15-30.
13. Liu L, Guo Q-X,. The driving forces in the inclusion complexation of cyclodextrins. J Incl PhenomMacroc Chem 2002; 42: 1-14.
14. Davis ME, Brewster ME,. Cyclodextrin-based pharmaceutics: past, present and future. Nature Rev 2004; 3: 1023-1035.
15. Loftsson T, et al. Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2004; 2: 261-275.
16. Uekama K,. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull 2004; 52: 900-915.
17. Loftsson T, et al. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005; 2: 335-351.
18. Dodziuk H,. Cyclodextrins and their complexes. Weinheim: Wiley-VCH Verlag, 2006.
19. Douhal A,. Cyclodextrin materials photochemistry, photophysics and photobiology. Amsterdam: Elsevier, 2006.
20. Brewster ME, Loftsson T,. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007; 59: 645-666.
21. Stella VJ, He Q,. Cyclodextrins. Tox Pathol 2008; 36: 30-42.
22. Larsen KL,. Large cyclodextrins. J Incl Phenom Macroc Chem 2002; 43: 1-13.
23. Ueda H, Endo T,. Large-ring cyclodextrins. In:, Dodziuk, H, ed. Cyclodextrins and their Complexes. Chemistry, Analytical Methods, Applications. Weinheim: Wiley-VCHVerlag, 2006: 370-380.
24. Frömming KH, Szejtli J,. Cyclodextrins in Pharmacy. Dordrecht: Kluwer Academic Publishers, 1994.
25. Szejtli J,. Cyclodextrin Technology. Dordrecht: Kluwer Academic Publishers, 1988.
26. Hirayama F, et al. Acid-catalyzed hydrolysis of maltosyl-β- cyclodextrin. J Pharm Sci 1992; 81: 913-916.
27. Szejtli J,. The metabolism, toxicity and biological effects of cyclodextrins. In:, Duchêne D, ed. Cyclodextrins and their Uses. Paris: Editions de Santé, 1987: 173-212.
28. Munro IC, et al. Safety assessment of β-cyclodextrin. Regul Toxicol Pharmacol 2004; 39 (Suppl. 1): S3-S13.
29. Antlsperger G, Schmid G,. Toxicological comparison of cyclodextrins. In:, Szejtli J, Szente L, eds. Proceedings of the Eighth International Symposium on Cyclodextrins. Budapest, Hungary, March 32-April 2, 1996. Dordrecht: Kluwer Academic Publishers, 1996: 149-155.
30. Antlsperger G,. New aspects in cyclodextrin toxicology. In:, Hedges AR, ed. Minutes of the Sixth International Symposium on Cyclodextrins. Paris: Editions de Santé, 1992: 277-283.
31. 14C-β-cyclodextrin in germfree and conventional rats. Regul Toxicol Pharmacol 1998; 27: 150-158.
32. 14C-γ-cyclodextrin in germ-free and conventional rats. Regul Toxicol Pharmacol 2004; 39: S57-S66.
33. Zhou H, et al. A pharmacokinetic study of intravenous intraconazole followed by oral administration of intraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 1998; 38: 593-602.
34. Lina BAR, Bär A,. Subchronic (13-week) oral toxicity study of α-cyclodextrin in dogs. Regul Toxicol Pharmacol 2004; 39: S27-S33.
35. Lina BAR, Bär A,. Subchronic oral toxicity studies with α-cyclodextrin in rats. Regul Toxicol Pharmacol 2004; 39: S14-S26.
36. Bellringer ME, et al. β-Cyclodextrin: 52-week toxicity studies in the rat and dog. Food Chem Toxicol 1995; 367-376.
37. Gould S, Scott RC,. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol 2005; 43: 1451-1459.
38. Schramm E, et al. Kit for the preparation of technetium TC 99m teboroxime myocardial perfusion agent. US Patent No. 6056941, 2000.
39. Stella VJ, et al. Mechanism of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 1999; 36: 3-16.
40. Hirayama F, Uekama K,. Methods of investigating and preparing inclusion compounds. In:, Duchêne D, ed. Cyclodextrins and Their Industrial Uses. Paris: Editions de Santé, 1987: 131-172.
41. Higuchi T, Connors KA,. Phase-solubility techniques. Adv Anal Chem Instrum 1965; 4: 117-212.
42. Repta AJ,. Alteration of apparent solubility through complexation. In:, Yalkowski SH, ed. Techniques of Solubilization of Drugs. New York: Marcel Dekker, 1985: 135-157.
43. Bonini M, et al. Self-assembly of β-cyclodextrin in water. Part 1: Cryo-TEM and dynamic and static light scattering. Langmuir 2006; 22: 1478-1484.
44. Wu A, et al. Micrometer-sized rodlike structure formed by the secondary assembly of cyclodextrin nanotube. J Coll Interf Sci 2006; 302: 87-94.
45. Wu A, et al. Investigation of γ-cyclodextrin nanotube induced by N,N′-diphenylbenzidine molecule. J Coll Interf Sci 2006; 297: 525-533.
46. Kajtár M, et al. Aggregation of amphotericin B in the presence of γ-cyclodextrin. Biopolymers 1989; 28: 1585-1596.
47. Coleman AW, et al. Aggregation of cyclodextrins: an explanation of the abnormal solubility of β-cyclodextrin. J Incl Phenom Macroc Chem 1992; 13: 139-143.
48. Andronati SA, et al. Inclusion compounds of psychotropic agents and cyclodextrins. J Incl Phenom Macroc Chem 1996; 24: 175-186.
49. Correia I, et al. Study of inclusion complexes of acridine with β-and (2,6-di-O-methyl)-β-cyclodextrin by use of solubility diagrams and NMR spectroscopy. J Phys Org Chem 2002; 15: 647-659.
50. Gabelica V, et al. On the specificity of cyclodextrin complexes detected by electrospray mass spectrometry. J Am Soc Mass Spectrom 2002; 13: 946-953.
51. Loftsson T, et al. Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci 2004; 93: 1091-1099.
52. Bikádi Z, et al. Aggregation of cyclodextrins as an important factor to determine their complexation behavior. Chem Biodiv 2006; 3: 1266-1276.
53. Yan P, et al. Interaction between β-cyclodextrin and mixed cationic-anionic surfactants (2): aggregation behavior. J Dispers Sci Technol 2007; 28: 623-626. (Pubitemid 46745511)
54. Loftsson T, et al. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005; 302: 18-28.
55. Loftsson T,. Effects of cyclodextrins on the chemical stability of drugs in aqueous solutions. Drug Stability 1995; 1: 22-33.
56. Sinko PJ,. Martin's Physical Pharmacy and Pharmaceutical Sciences. Philadelphia: Lippincott Williams & Wilkins, 2006.
57. Gelb RI, et al. Cycloamylose complexation of organic anions. J Phys Chem 1982; 87: 3349-3354.
58. Gelb RI, et al. Binding mechanisms in cyclohexaamylose complexes. J Am Chem Soc 1981; 103: 1750-1757.
59. Matsuyama K, et al. Thermodynamics of binding of aromatic amino acids to α-, β- and γ-cyclodextrin. Drug Dev Ind Pharm 1987; 13: 2687-2691.
60. Kurihara M, et al. Improvement of some pharmaceutical properties of cloprost by β- and γ-cyclodextrin complexation. J Incl Phenom Molec Recogn Chem 1990; 8: 363-373.
61. Tong W-Q, et al. Microcalorimetric investigation of the complexation between 2-hydroxypropyl-β-cyclodextrin and amine drugs with diphenylmethyl functionality. J Pharm Biomed Anal 1991; 9: 1139-1146.
62. Ross PD, Rekharsky MV,. Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes. Biophys J 1996; 71: 2144-2154.
63. Rekharsky MV, Inoue Y,. Complexation thermodynamics of cyclodextrins. Chem Rev 1998; 98: 1875-1917.
64. Bergeron RJ,. Cycloamylose-substrate binding. In:, Attwood JL, et al., eds. Inclusion Compounds. London: Academic Press, 1984: 391-443.
65. Szejtli J,. Cyclodextrins and their Inclusion Complexes. Budapest: Akademiai Kiadó, 1982.
66. Loftsson T, et al. Methods to enhance the complexation efficiency of cyclodextrins. STP Pharma Sci 1999; 9: 237-242.
67. Loftsson T, Bodor N,. Effects of 2-hydroxypropyl-β-cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17β-estradiol. Acta Pharm Nord 1989; 1: 185-194. (Pubitemid 19247949)
68. Hussain MA, et al. Complexation of moricizine with nicotinamide and evaluation of the complexation constants by various methods. J Pharm Sci 1993; 82: 77-79.
69. Krishnamoorthy R, Mitra AK,. Complexation of weak acids and bases with cyclodextrins: effects of substrate ionization on the estimation and interpretation of association constants. Int J Pharm Adv 1996; 1: 330-343.
70. Li P, et al. Combined effect of complexation and pH on solubilization. J Pharm Sci 1998; 87: 1535-1537.
71. Piel G, et al. Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins. Int J Pharm 1998; 169: 15-22.
72. Redenti E, et al. Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J Pharm Sci 2001; 90: 979-986.
73. Granero G, et al. The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-β-cyclodextrin. Eur J Pharm Sci 2003; 20: 285-293.
74. Loftsson T, et al. Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie 2004; 59: 25-29.
75. Tinwalla AY,. et al. Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation with 2-hydroxypropyl-β- cyclodextrin. Pharm Res 1993; 10: 1136-1143.
76. Selva A, et al. Study of β-cyclodextrin-ketoconazole-tartaric acid multicomponent non-covalent association by positive and netagive ionspray mass spectrometry. J Mass Sepectrom 1998; 33: 729-734.
77. Fenyvesi E, et al. Interaction of hydroxy acids with β-cyclodextrin. J Incl Phenom Macroc Chem 1999; 33: 339-344.
78. Redenti E, et al. Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J Pharm Sci 2000; 89: 1-8.
79. Mura P, et al. Ternary systems of naproxen with hydroxypropyl β-cyclodextrin and aminoacids. Int J Pharm 2003; 260: 293-302.
80. Loftsson T, Másson M,. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J Drug Deliv Sci Tech 2004; 14: 35-43.
81. Yamakawa T, Nishimura S,. Liquid formulation of a novel non-fluorinated topical quinolone, T-3912, utilizing the synergic solubilizing effect of the combined use of magnesium ions and hydroxypropyl-β-cyclodextrin. J Control. Release 2003; 86: 101-113.
82. Furuta T, et al. Effects of water of inclusion complexes of d-limonene and cyclodextrins. Supramol Chem 1993; 1: 321-325.
83. Li P, et al. Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. J Pharm Sci 1999; 88: 1107-1111.
84. Zia V, et al. Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7M-β-CD to HP-β-CD. Pharm Res 2001; 18: 667-673.
85. Higuchi T,. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmetic Chemists 1960; 11: 85-97.
86. Flynn GL, Yalkowsky SH,. Correlation and prediction of mass transport across membranes I: influence of alkyl chain length on flux-determining properties of barrier and diffusant. J Pharm Sci 1972; 61: 838-852.
87. Flynn GL, et al. Total mathematical resolution of diffusion layer control of barrier flux. J Pharm Sci 1972; 61: 312-314.
88. Loftsson T, et al. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 2007; 96: 2532-2546.
89. Smart JD,. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 2005; 57: 1556-1568.
90. Cu Y, Saltzman WM,. Mathematical modeling of molecular diffusion through mucus. Adv Drug Deliv Rev 2009; 61: 101-114.
91. Amidon GL, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
92. Stella VJ, Rajewski RA,. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997; 14: 556-567.
93. 3H]benzo[a]pyrene in the rat. J Pharm Sci 2005; 94: 114-119.
94. Muller BW, Alberts E,. Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on thepharmacokinetics of the drugs. J Pharm Sci 1991; 80: 599-604.
95. Stella VJ, et al. The effect of SBE4-β-CD on i.m. prednisolone pharmacokinetics and tissue damage in rabbits: comparison to a co-solvent solution and a water-soluble prodrug. Int J Pharm 1995; 120: 197-204.
96. Piel G, et al. Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution. Int J Pharm 1999; 180: 41-45.
97. Zuo Z, et al. Hydroxypropyl-β-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. J Pharm Pharm Sci 2002; 5: 300-306.
98. Egan TD, et al. The pahrmacokinetics and pharmacodynamics of propofol in modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 2003; 97: 72-79.
99. McIntosh MP, et al. In vitro and in vivo evaluation of a sulfobutyl ether β-cyclodextrin enabled etomidate formulation. J Pharm Sci 2004; 93: 2585-2594.
100. Liu J, et al. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-β-cyclodextrin. Int J Pharm 2006; 312: 137-143.
101. Buggins TR, et al. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 2007; 59: 1482-1503.
102. Adam JM, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002; 45: 1806-1816.
103. Welliver M,. New drug sugammadex: a selective relaxant binding agent. AANA J 2006; 74: 357-363.
104. Perry CS, et al. The binding interaction of synthetic ozonide antimalarials with natural and modified β-cyclodextrins. J Pharm Sci 2006; 95: 146-158.
105. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci 2006; 95: 256-267.
106. Loftsson T, Järvinen T,. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 1999; 36: 59-79.
107. Challa R, et al. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 2005; 6: E329-E357.
108. Carrier RL, et al. The ultility of cyclodextrins for enhancing oral bioavailability. J Control. Release 2007; 123: 78-99.
109. Cal K, Centkowska K,. Use of cyclodextrins in topical formulations: practical aspects. Eur J Pharm Biopharm 2008; 68: 467-478.
110. Vyas A, et al. Cyclodextrin based novel drug delivery systems. J Incl Phenom Macroc Chem 2008; 62: 23-42.
111. Wenz G,. An overview of host-guest chemistry and its application to nonsteroidal anti-inflammatory drugs. Clin Drug Invest 2000; 19 (Suppl. 2): 21-25.
112. Redenti E, et al. A study on the differentiation between amorphous piroxicam: β-cyclodextrin complex and a mixture of the two amorphous components. Int J Pharm 1996; 129: 289-294.
113. Woodcock BG, et al. Supermolecular inclusion of piroxicam xith β-cyclodextrin: pharmacokinetic properties in man. Eur J Rheumatol Inflamm 1993; 12: 12-28.
114. McEwen J,. Clinical pharmacology of piroxicam-β-cyclodextrin. Implications for innovative patient care. Clin Drug Invest 2000; 19 (Suppl. 2): 27-31.
115. Kim Y, et al. Inclusion complexes of arylheterocyclic salts. United States Patent No. 6,232,304 B1, May 15, 2001.
116. Kim Y, et al. Inclusion of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether. J Pharm Sci 1998; 87: 1560-1567.
117. Konrádsdóttir F, Loftsson T,. Fish skin as a model membrane: structure and characteristics. J Pharm Pharmacol 2009; 61: 121-124.
118. Moffat AC, et al. Clarke's Analysis of Drugs and Poisons. 3rd edn. London: Pharmaceutical Press, 2004.
119. 2O: a comparative study. Carbohydr Res 2006; 341: 270-274.
120. Connors KA,. Population characteristics of cyclodextrin complex stabilities in aqueous solution. J Pharm Sci 1995; 84: 843-848.
121. Connors KA,. The stability of cyclodextrin complexes in solution. Chem Rev 1997; 97: 1325-1357.
122. Loftsson T, et al. The complexation efficiency. J Incl Phenom Macroc Chem 2007; 57: 545-552.
123. Peeters J, et al. Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci 2002; 91: 1414-1422.
124. Loftsson T, et al. Cyclodextrin complexation of NSAIDs: physicochemical characteristics. Eur J Pharm Sci 1993; 1: 95-101.